Logo Image
News
All News
Publications
All PublicationsPharmTechPharmTech Europe
Multimedia
All VideosAsk the ExpertBehind The HeadlinesDrug Digest VideosDrug Solutions PodcastShorts
Conferences
Conference CoverageConference Listing
More
Webcasts
Resources
ICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPartnersPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksState of the ScienceWhitepapers

Subscribe

  • News
  • Publications
  • Multimedia
  • Conferences
  • Webcasts
  • Resources
  • Subscribe
  • Analytics
    • Bio/Pharmaceutical Analysis Techniques
    • Laboratory Equipment and Instruments
  • Data and Artificial Intelligence
  • Dosage Forms
    • Solid/Semi-Solid Dosage
    • Specialty Dosage Drugs
    • Parenterals and Injectables
    • Inhalation Drugs
  • Drug Development
    • Intellectual Property and Patents
    • Process and Scaling
    • APIs and Excipients
    • Ingredients
    • Formulation and Drug Delivery
  • Manufacturing
    • Aseptic/Sterile Processing
    • Equipment
    • Process and Automation
    • Manufacturing, Parenterals and Injectables
    • Manufacturing, Biosimilars and Biobetters
    • Manufacturing, Inhalation Drugs
    • Manufacturing, Solid and Semi-Solid Dosage Drugs
    • Manufacturing, Cell Therapies
    • Manufacturing, Biologic Drugs
    • Supply Chain
    • Manufacturing, Gene Therapies
    • Packaging and Distribution
  • Outsourcing
    • Contract Research Services
    • Contract Analytical Services
    • Contract Development Services
    • Regulatory Consulting
    • Logistics and Distribution
    • Contract Manufacturing Services
  • Quality Systems
    • Ask the Expert
    • Quality Assurance/Quality Control
    • Regulatory Oversight and Compliance
Spotlight -
Analytics|
Dosage Forms|
Drug Development|
Manufacturing|
Outsourcing|
Quality Systems
Advertisement

Yueer Shi

Advertisement

Yueer Shi is group leader, Bristol Myers Squibb, USA, [email protected]

Articles by Yueer Shi

Covalidation Strategies to Accelerate Analytical Method Transfer for Breakthrough Therapies

ByYueer Shi,Nicola Hulme,Kieran O’Connor
April 2nd 2017

The primary impact of using the covalidation model is the expedited analytical method qualification of both the transferring and receiving laboratories.

Advertisement

Latest Updated Articles

  • Covalidation Strategies to Accelerate Analytical Method Transfer for Breakthrough Therapies
    Covalidation Strategies to Accelerate Analytical Method Transfer for Breakthrough Therapies

    April 2nd 2017



Advertisement
Advertisement

Trending on Pharmaceutical Technology

1

Pharma Fundamentals: Hold Times in Biopharmaceuticals

2

Zumilokibart: Inside AbbVie's $10.9B Pipeline Bet

3

Why Pharma Dealmaking Slowed in Q1 2026 and What Is Coming Next

4

IPEC’s Excipient Information Package: A Standardized Communication Platform for Sharing Excipient Information as an Alternative to Questionnaires

5

Merck KGaA Launches Saturnus Bio; Announces Awards

  • About Us
  • Advertise
  • Contact Us
  • Editorial Info
  • Editorial Advisory Board
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us